Free Trial
→ Elon Now Pays 15X More Than Your Bank (From InvestorPlace) (Ad)tc pixel
NASDAQ:LTRN

Lantern Pharma Q1 2026 Earnings Report

Lantern Pharma logo
$3.84 +0.44 (+13.00%)
Closing price 03:59 PM Eastern
Extended Trading
$3.82 -0.03 (-0.70%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Lantern Pharma EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Lantern Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lantern Pharma Announcement Details

Quarter
Q1 2026
Date
5/15/2026
Time
After Market Closes
Conference Call Date
Friday, May 15, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Lantern Pharma's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Lantern Pharma's Q1 2026 Press ReleasePress Release
(8-K)
Lantern Pharma's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Lantern Pharma Earnings Headlines

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
June 2 at 8:13 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260602549826/en/lantern-pharma-reports-harmonic%e2%84%a2-data-showing-lp-300-progression-free-survival-benefit-deepens-with-treatment-duration-in-egfr-exon-21-l858r-lung-cancer/
Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress
June 2 at 6:51 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lantern-pharma-highlights-harmonic-lp-300-phase-2-progress?utm_source=marketbeat.com&utm_medium=referral
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
June 4 at 1:00 AM  |  Porter & Company (Ad)
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript
May 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/lantern-pharma-ltrn-q1-2025-143934474.html
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519628990/en/lantern-pharma-announces-successful-outcome-of-fda-type-c-meeting-request-for-harmonic%e2%84%a2-phase-2-trial-of-lp-300-in-never-smokers-with-nsclc/
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260515994237/en/lantern-pharma-reports-first-quarter-2026-financial-results-and-provides-business-updates/
See More Lantern Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lantern Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantern Pharma and other key companies, straight to your email.

About Lantern Pharma

Lantern Pharma (NASDAQ:LTRN), Inc. is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need. Lead programs include LP-100, an alkylating agent advancing toward clinical evaluation in metastatic castration-resistant prostate cancer, and LP-184, a next-generation DNA-targeting compound in preclinical development for multiple solid tumors, including pancreatic and ovarian cancers. Lantern Pharma aims to streamline drug development timelines and reduce attrition rates by using AI-driven insights to inform preclinical and clinical strategies.

Lantern Pharma has established collaborations with institutions such as the National Cancer Institute’s Cancer Therapy Evaluation Program and academic partners to validate its platform and progress its candidates through regulatory pathways. The company’s approach blends computational analytics with traditional pharmacology, positioning Lantern to address the growing demand for precision oncology solutions. As it advances its pipeline, Lantern Pharma seeks to deliver new therapeutic options for patients and create long-term value through a data-driven development model.

View Lantern Pharma Profile
Earnings Tools